Form 4: PepGen Inc. CFO Noel Donnelly Reports Acquisition of Stock Options and Restricted Stock Units

Chief Financial Officer Noel Donnelly of PepGen Inc. reports the acquisition of stock options and restricted stock units, along with the disposal of some common stock.

Summary

• On March 3, 2025, Noel Donnelly, the CFO of PepGen Inc., reported transactions involving the company's securities.
• Donnelly acquired 23,283 shares of common stock through restricted stock units (RSUs) at a price of $0.
• These RSUs vest in equal annual installments over four years, starting March 3, 2026, contingent upon continued service with the company.
• Donnelly also acquired stock options for 104,250 shares with an exercise price of $2.81, vesting 25% on March 3, 2026, and the remainder in 36 equal monthly installments.
• Additionally, Donnelly disposed of some common stock, resulting in a total of 24,956 shares beneficially owned following the reported transactions.
• The reported transactions include the acquisition of 104,250 derivative securities (stock options) at a price of $0.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of RSUs and options suggests confidence, but the disposal of some shares tempers the positive outlook.

Positives

• The acquisition of RSUs and stock options by the CFO could be interpreted as a positive sign, indicating confidence in the company's future performance.

Negatives

• The disposal of some common stock by the CFO could be interpreted as a negative sign, indicating a lack of confidence in the company's future performance.

Risks

• The vesting of RSUs and stock options is contingent upon continued service with the company, creating a potential risk if the CFO were to leave before the vesting dates.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a long-term commitment from the CFO to the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The acquisition of equity by executives is generally viewed positively, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Equity compensation is a common practice in the biotechnology industry to attract and retain talent.
• Vesting schedules are typically structured to incentivize long-term performance and commitment.
• Comparing the size and terms of these grants to those of peer companies would provide further context on their competitiveness.

Stakeholder Impact

• The transactions could have a minor impact on shareholder sentiment, depending on how they interpret the CFO's actions.
• Employees may view the equity grants as a positive sign of the company's commitment to its leadership.

Key Dates